Clinical Trial Applications - Approved: Filter, Search, and view applications
| # | Protocol No | Study Title | Investigator(s) & Site(s) | Date Approved | |
|---|---|---|---|---|---|
191. |
ECCT/18/11/02 | EPI 003 A prospective study to evaluate the safety, effectiveness and impact of the RTS,S/AS01E vaccine in young children in sub-Saharan Africa. |
Principal Investigator(s) 1. BERNHARDS OGUTU Site(s) in Kenya 1. • Ahero Clinical Trials Unit (Kisumu county) 2. KEMRI Walter Reed Army Institute of Research (Kisumu county) 3. KEMRI CDC SIAYA (Siaya county) |
25-03-2019 |
View |
192. |
ECCT/21/11/02 | SONIA Trial A Pragmatic Randomized Controlled Trial of Standard Care versus Steroids plus Standard Care for Treatment of Pneumonia in Adults Admitted to Kenyan Hospitals |
Principal Investigator(s) 1. Anthony Oliwa Etyang 2. Samuel Owuor Akech Site(s) in Kenya 1. Kilifi County Hospital (Kilifi county) 2. Mbagathi Sub-county Hospital (Nairobi City county) 3. Busia County Referral Hospital (Busia county) 4. Bungoma County Referral Hospital (Bung\'oma county) 5. Kisumu County Hospital (Kisumu county) 6. Machakos Level 5 Hospital (Machakos county) 7. Mama Lucy Kibaki Hospital (Nairobi City county) 8. Kitale County Referral Hospital (Trans Nzoia county) 9. Kiambu County Hospital (Kiambu county) 10. Kakamega County Hospital (Kakamega county) |
06-04-2022 |
View |
193. |
ECCT/24/11/03 | REALISE STUDY PROTOCOL A Pragmatic Phase III Multi-Centre Clinical Trial to Evaluate the Safety and 1 Effectiveness of a Single Dose of an Albendazole-Ivermectin Coformulation vs 2 Albendazole for Preventive Chemotherapy of Soil-Transmitted Helminth Infections in 3 School-Aged Children |
Principal Investigator(s) 1. Alejandro Javier Krolewiecki Site(s) in Kenya Kwale county |
19-06-2025 |
View |
194. |
ECCT/23/03/03 | Moderna 1273 A Phase 2/3, Randomized, Observer-Blind, Placebo‑Controlled Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA‑1273 SARS‑CoV‑2 Vaccine in Healthy Adolescents 12 to <18 Years of Age |
Principal Investigator(s) 1. Prof. Walter Godfrey Jaoko Jaoko Site(s) in Kenya 1. KAVI Institute of Clinical Reasearch, College of Health science (Nairobi City county) 2. Victoria Biomedical Research Institute (Kisumu county) 3. KEMRI/USAMRD (Kericho county) 4. Kenya Medical Research Institute/USAMRU (Kisumu county) 5. KEMRI CMR-Kar Geno Research Centre (Kisumu county) 6. KEMRI CRDR - Clinical Research Nairobi (Nairobi City county) 7. KEMRI/ CDC (Kisumu county) 8. KEMRI (Kisumu county) 9. KEMRI Centre for Clinical Research Butere County Hospital (Kakamega county) |
12-05-2023 |
View |
195. |
ECCT/25/11/03 | RSV IMPACT TRIAL A Phase-IIIb individually randomized, placebo-controlled trial on safety of RSVA/B-preF vaccine in pregnant women and efficacy against severe RSV-associated lower respiratory tract infection in infants. |
Principal Investigator(s) 1. Nancy A. Otieno 2. Evans M. Ogoti Site(s) in Kenya Kenya Medical Research Institute, Centre for Global Health Research - Siaya (KE1) |
09-02-2026 |
View |
196. |
ECCT/26/02/04 | RSV IMPACT TRIAL A Phase-IIIb individually randomized, placebo-controlled trial on safety of RSVA/B-preF vaccine in pregnant women and efficacy against severe RSV-associated lower respiratory tract infection (LRTI) in infants. |
Principal Investigator(s) 1. Joyce Uchi Nyiro 2. Makobu Kimani Site(s) in Kenya 1. Kilifi, KEMRI-Centre for Geographic Medicine Research Coast (CGMRC) (Kilifi county) |
28-05-2026 |
View |
197. |
ECCT/17/08/01 | A trial to compare the safety and immune response of the normal full and reduced doses of yellow fever vaccines in Kenyan adults A Phase IV randomized, double blinded non-inferiority trial on the immunogenicity and safety of fractional doses of yellow fever vaccines. |
Principal Investigator(s) 1. Philip Bejon Site(s) in Kenya KEMRI Kilifi |
07-09-2017 |
View |
198. |
ECCT/24/07/04 | AMC-114 A Phase III, Randomized, Open-Label, Non-Inferiority Study of Paclitaxel and Pegylated Liposomal Doxorubicin for Treatment of HIV-related Kaposi Sarcoma in Resource-Limited Settings |
Principal Investigator(s) 1. Dr. Naftali Busakhala Site(s) in Kenya Moi University Clinical Research Center |
03-12-2024 |
View |
199. |
ECCT/22/01/03 | lidERA A Phase III, Randomized, Open-Label, Multicenter Study Evaluating the Efficacy and Safety of Adjuvant Giredestrant Compared with Physician’s Choice of Adjuvant Endocrine Monotherapy in Patients with Estrogen Receptor-Positive, HER2-Negative Early Breast Cancer |
Principal Investigator(s) 1. Mansoor Saleh Site(s) in Kenya 1. International Cancer Institute (ICI) (Uasin Gishu county) 2. Aga Khan University Hospital (Nairobi City county) |
08-05-2022 |
View |
200. |
ECCT/21/11/07 | lidERA A PHASE III, RANDOMIZED, OPEN-LABEL, MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF ADJUVANT GIREDESTRANT COMPARED WITH PHYSICIAN'S CHOICE OF ADJUVANT ENDOCRINE MONOTHERAPY IN PATIENTS WITH ESTROGEN RECEPTORï€POSITIVE, HER2-NEGATIVE EARLY BREAST CANCER |
Principal Investigator(s) 1. Fredrick Asirwa Chite Site(s) in Kenya 1. International Cancer Institute (ICI) (Uasin Gishu county) 2. Aga Khan University Hospital (Nairobi City county) |
27-03-2022 |
View |